NewLimit secures $435M funding, valuation tops $3B, aims for human trials in 2027

NewLimit, a Bay Area anti-aging biotech, announced a financing round that raised $435 million, valuing the company at more than $3 billion.

The round is among the largest private biotech financings reported in 2026. Investors were not listed in the excerpt, but the capital will support development of the company’s first anti-aging drug candidate.

NewLimit plans to begin human clinical testing of the candidate in 2027, moving the program toward later-stage development.